Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Urology. 2014 Feb;83(2):369–375. doi: 10.1016/j.urology.2013.09.045

Table 1.

Incremental benefit of apparent diffusion coefficient in delineating varying definitions of significant prostate cancer

Epstein Alone Epstein + ADC <850 µm2/s
Pathologic Findings N (%) Sens, % Spec, % PPV, % NPV, % Sens, % Spec, % PPV, % NPV, %
Gleason >6 Any Size or Gleason = 6 and Tumor Volume ≥0.2 mL 90 (87) 70 71 94 27 81 57 92 32
Gleason >6 Any Size or Gleason = 6 and Tumor Volume ≥0.5 mL 87 (84) 70 65 91 30 82 53 90 36
Gleason >6 Any Size or Gleason = 6 and Tumor Volume ≥1.3 mL 76 (73) 76 68 87 51 87 54 84 60
Gleason >6 and Any Size 58 (56) 79 54 69 68 93 46 68 84
Gleason >3 + 4 Any Size or Gleason = 7 and Tumor Volume ≥0.2 mL 58 (56) 79 54 69 68 93 46 68 84
Gleason >3 + 4 Any Size or Gleason = 7 and Tumor Volume ≥0.5 mL 58 (56) 79 54 69 68 93 46 68 84
Gleason >3 + 4 Any Size or Gleason = 7 and Tumor Volume ≥1.3 mL 54 (52) 81 54 66 73 96 46 66 92

ADC, apparent diffusion coefficient; NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.